Interleukin-23 Antagonist [EPC]

108855 reported adverse events

Drugs of this class: GUSELKUMAB RISANKIZUMAB-RZAA TILDRAKIZUMAB-ASMN USTEKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-23 Antagonist [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	12911
1	PSORIASIS	10055
2	OFF LABEL USE	8909
3	PRODUCT DOSE OMISSION ISSUE	7617
4	FATIGUE	4968
5	PAIN	4662
6	PRODUCT USE ISSUE	4507
7	ARTHRALGIA	4425
8	HEADACHE	4096
9	RASH	3754

See all common reactions for Interleukin-23 Antagonist [EPC]

Drugs of the Interleukin-23 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	SWOLLEN JOINT COUNT INCREASED	550	0.6381
1	LUPUS VULGARIS	65	0.5603
2	RHEUMATIC FEVER	671	0.5527
3	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY	92	0.5287
4	RED BLOOD CELL SEDIMENTATION RATE	127	0.5100
5	DEEP VEIN THROMBOSIS POSTOPERATIVE	153	0.4842
6	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	1665	0.4626
7	RHEUMATOID FACTOR POSITIVE	1450	0.4459
8	DUODENAL ULCER PERFORATION	946	0.2953
9	C-REACTIVE PROTEIN	54	0.2769

See all enriched reactions for Interleukin-23 Antagonist [EPC]